Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Three hunters captured a massive Burmese python in the Florida Everglades on May 31, 2025. The longest Burmese python ever recorded was 19 feet long, caught in 2023. The heaviest python caught weighed ...

It's a nightmare for any traveler: getting to the airport and not having their ID. For many Americans, a version of that headache will become a reality starting today when the federal government ...

Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time ...

A Real Pain”—an acclaimed comedy starring Jesse Eisenberg and Kieran Culkin—is coming soon to digital streaming. A Real Pain—which is also written and directed by Eisenberg—was released in theaters on ...

An experimental ‘no-GIL’ build mode in Python 3.13 disables the Global Interpreter Lock to enable true parallel execution in Python. Here’s where to start. The single biggest new feature in Python ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products. While this small biotech looks promising, it ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased ...

Salt Lake City-based Recursion Pharmaceuticals is joining forces with the United Kingdom’s Exscientia, a biotechnology company that specializes in cancer research, in a $688 million deal executives ...